Objectives. To evaluate the clinical effect of intraperitoneal hypert hermic ch emotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospec tively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed a t the Gynecology Department of Kangnam St. Marys Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conven tional treatment)with IPHC and 60 patients (control group) underwent conventiona l treatment only. IPHC consisted of administering a mixture of 350 mg/m2 of carb oplatin and 5,000,000 IU/m2 of interferon-α, and maintaining the intraperitone al temperature at 43-44°C during surgery. Results. The overall 5-year surviva l rate was 58.6%; that of the IPHC group was 63.4%vs. 52.8%in the control group, w ith significantly higher survival in the IPHC group (P = 0.0078). Considering st age III ovarian cancer patients only (n = 74), the survival rate was 53.8%in th e IPHC group (n = 35) and 33.3%in the control group (n = 39) and was significan tly higher in the IPHC group (P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), t he 5-year survival rate was 65.6%in patients who underwent IPHC (n = 26) and 4 0.7%in the control patients (n = 27) (P = 0.0046). IPHC was an independent prog nostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0 .496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new t reatment modality in ovarian cancer. Objectives. To evaluate the clinical effect of intraperitoneal hyperthemic ch emotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospec tively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary Hospitals Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conven tional treatment) with IPHC and 60 patients (control group) underwent conventiona l treatment only. IPHC consisted of a mixture of 350 mg / m2 of carb oplatin and 5,000,000 IU / m2 of interferon-α, and maintain the intraperitoneal temperature at 43-44 ° C during surgery. Results. The overall 5-year surviva l rate was 58.6%; that of the IPHC group was 63.4% vs . Considering age of ovarian cancer patients only (n = 74), the survival rate was 53.8% in th e IPHC group (n = 35) and 33.3% i For the stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure (n = 53), t (n = 39) and was significantly higher than the IPHC group The 5-year survival rate was 65.6% in patients who underwent IPHC (n = 26) and 4 0.7% in the control patients (n = 27) (P = 0.0046). IPHC was an independent prog nostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new reatment modality in ovarian cancer.